-
公开(公告)号：US08333965B2
公开(公告)日：2012-12-18
申请号：US13252335
申请日：2011-10-04
IPC分类号： A61K39/395 , A61K38/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（IFNα）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1，K的生物活性的抗体， 4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20090214565A1
公开(公告)日：2009-08-27
申请号：US12367030
申请日：2009-02-06
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H 2，I，J 1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20140154239A1
公开(公告)日：2014-06-05
申请号：US13705289
申请日：2012-12-05
IPC分类号： C07K16/24
CPC分类号： C07K16/249 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20080160030A1
公开(公告)日：2008-07-03
申请号：US11883961
申请日：2006-02-09
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的蛋白质亚型的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US08080638B2
公开(公告)日：2011-12-20
申请号：US11883961
申请日：2006-02-09
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括M×A启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US07888481B2
公开(公告)日：2011-02-15
申请号：US12367030
申请日：2009-02-06
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20080286314A1
公开(公告)日：2008-11-20
申请号：US11932095
申请日：2007-10-31
CPC分类号： A61K35/28 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , A61K2039/6043
摘要： The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
摘要翻译： 本发明包括用于分离，纯化和制备用于生产定制的癌症疫苗的免疫原性抗原的组合物和方法，其包括与包含热休克癌细胞的抗原接触的树突状细胞。
-
公开(公告)号：US20080112962A1
公开(公告)日：2008-05-15
申请号：US11931765
申请日：2007-10-31
IPC分类号： A61K39/00
CPC分类号： A61K35/28 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , A61K2039/6043
摘要： The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
摘要翻译： 本发明包括用于分离，纯化和制备用于生产定制的癌症疫苗的免疫原性抗原的组合物和方法，其包括与包含热休克癌细胞的抗原接触的树突状细胞。
-
公开(公告)号：US20060140983A1
公开(公告)日：2006-06-29
申请号：US11257951
申请日：2005-10-25
CPC分类号： A61K35/28 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , A61K2039/6043
摘要： The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
摘要翻译： 本发明包括用于分离，纯化和制备用于生产定制的癌症疫苗的免疫原性抗原的组合物和方法，其包括与包含热休克癌细胞的抗原接触的树突状细胞。
-
公开(公告)号：US20080112924A1
公开(公告)日：2008-05-15
申请号：US11931317
申请日：2007-10-31
CPC分类号： A61K35/28 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , A61K2039/6043
摘要： The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.032 秒)